Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, yesterday FDA Aprroved Oral Endoxifen for breast cancer patient. Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to prevent new as well as recurrent disease in breast cancer patients.
This good news bring positive impact to Atossa stocks. Yesterday Atossa rose 395.26%, and this price movement is nothing if we compare with monthly range at past few years.
For long term investment, We have 24000% profit projection at 128.75 and 90000% maximum profit projection at 479
C'mon really? Long term target of $128.75 and $479???? You do realize it split awhile ago right? Which completely negates your "technical analysis". You might as well say, "target 1 million dollars", Austin Powers style.
Don't be ridiculous.
Don't be a scam artist. You have no idea what you are doing and are hurting people by leading them astray with this nonsense. You should be ashamed of yourself.
harmvanboven
⋅
@NicAdams, "show me the charts, and i'll tell you the news." bernard baruch.
Look at some of here previous charts.